Immunosenescence in Human Disease: Mechanistic Insights and Therapeutic Opportunities.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic concepts without systematic methodology or primary human data
PubMed 41755768 · doi:10.4062/biomolther.2025.222
What was done
The authors synthesized literature on the features of immunosenescence, biomarkers for assessing immune aging (such as phenotypic markers, telomere attrition, and epigenetic signatures), mechanistic links to autoimmune, metabolic, and neurodegenerative diseases, and therapeutic strategies including senolytics, mTOR inhibitors, cytokine modulation, and epigenetic reprogramming.
What was found
No quantitative data or specific numerical results are reported in the abstract. The authors qualitatively describe mechanisms including thymic involution, loss of naive T cells, contraction of T-cell receptor diversity, accumulation of senescent/exhausted lymphocytes, and inflammaging, linking these processes to tissue damage and neuronal loss.
Why it matters
It provides a broad conceptual overview connecting immune decline to diverse age-related pathologies and highlights potential therapeutic targets for restoring immune competence.
Limits
As a narrative review, it presents no original empirical data, systematic search methodology, or quantitative synthesis. The abstract provides no sample sizes, effect estimates, or clinical trial outcomes to evaluate therapeutic efficacy.
Cited by
- supports As the immune system ages, it shifts from specific responses toward non-specific inflammatory responses.